目的观察冠状动脉内注射比伐卢定对急性非ST段抬高型心肌梗死(NSTEMI)高危患者早期行经皮冠状动脉介入治疗(PCI)术预后的影响。方法 选择2016年1月—2018年8月邢台市第三医院心内科诊治的NSTEMI高危患者115例作为研究对象,采用随机数字...目的观察冠状动脉内注射比伐卢定对急性非ST段抬高型心肌梗死(NSTEMI)高危患者早期行经皮冠状动脉介入治疗(PCI)术预后的影响。方法 选择2016年1月—2018年8月邢台市第三医院心内科诊治的NSTEMI高危患者115例作为研究对象,采用随机数字表法分为对照组58例、观察组57例。患者均按照冠心病诊疗规范治疗并予PCI;术中对照组患者给予肝素钠注射液抗凝,观察组给予比伐卢定抗凝至术后4 h。比较2组患者罪犯血管术前、术后校正的心肌梗死溶栓(TIMI)血流计帧数(CTFC)、活化凝血时间(ACT)、血清氨基末端脑钠肽前体(NT-proBNP)浓度、心电图QRS波时限、心脏超声结果及不良事件发生率。结果 术后观察组患者罪犯靶血管CTFC明显低于对照组( t/P =2.429/0.027);2组患者术后ACT检测值差异均无统计学意义( P >0.05);2组患者术前心电图QRS波时限、心脏超声左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、室间隔厚度(IVSd)、血清NT-proBNP含量比较,差异均无统计学意义( P >0.05);术后90 d时观察组患者QRS波时限、血清NT-proBNP低于对照组( t/P =2.019/0.042,2.461/0.037),随访90 d不良事件发生率低于对照组患者(χ 2/ P =4.294/0.045)。术后180 d,观察组、对照组患者左室射血分数均高于术前,且观察组较对照组明显升高( t =4.748,2.027,2.239, P =0.000,0.035, 0.039 );另外,术后180d观察组左室舒张末内径(LVEDD)、室间隔厚度(IVSd)明显低于对照组( t =1.985,2.223, P =0.049,0.039)。结论 冠状动脉内应用比伐卢定可进一步改善NSTEMI高危患者早期PCI术的预后,值得临床推广应用。展开更多
Use of extracorporeal membrane oxygenation to support patients with critical cardiorespiratory illness is increasing.Systemic anticoagulation is an essential element in the care of extracorporeal membrane oxygenation ...Use of extracorporeal membrane oxygenation to support patients with critical cardiorespiratory illness is increasing.Systemic anticoagulation is an essential element in the care of extracorporeal membrane oxygenation patients.While unfractionated heparin is the most commonly used agent,unfractionated heparin is associated with several unique complications that can be catastrophic in critically ill patients,including heparin-induced thrombocytopenia and acquired antithrombin deficiency.These complications can result in thrombotic events and subtherapeutic anticoagulation.Direct thrombin inhibitors(DTIs)are emerging as alternative anticoagulants in patients supported by extracorporeal membrane oxygenation.Increasing evidence supports DTIs use as safe and effective in extracorporeal membrane oxygenation patients with and without heparininduced thrombocytopenia.This review outlines the pharmacology,dosing strategies and available protocols,monitoring parameters,and special use considerations for all available DTIs in extracorporeal membrane oxygenation patients.The advantages and disadvantages of DTIs in extracorporeal membrane oxygenation relative to unfractionated heparin will be described.展开更多
文摘目的观察冠状动脉内注射比伐卢定对急性非ST段抬高型心肌梗死(NSTEMI)高危患者早期行经皮冠状动脉介入治疗(PCI)术预后的影响。方法 选择2016年1月—2018年8月邢台市第三医院心内科诊治的NSTEMI高危患者115例作为研究对象,采用随机数字表法分为对照组58例、观察组57例。患者均按照冠心病诊疗规范治疗并予PCI;术中对照组患者给予肝素钠注射液抗凝,观察组给予比伐卢定抗凝至术后4 h。比较2组患者罪犯血管术前、术后校正的心肌梗死溶栓(TIMI)血流计帧数(CTFC)、活化凝血时间(ACT)、血清氨基末端脑钠肽前体(NT-proBNP)浓度、心电图QRS波时限、心脏超声结果及不良事件发生率。结果 术后观察组患者罪犯靶血管CTFC明显低于对照组( t/P =2.429/0.027);2组患者术后ACT检测值差异均无统计学意义( P >0.05);2组患者术前心电图QRS波时限、心脏超声左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、室间隔厚度(IVSd)、血清NT-proBNP含量比较,差异均无统计学意义( P >0.05);术后90 d时观察组患者QRS波时限、血清NT-proBNP低于对照组( t/P =2.019/0.042,2.461/0.037),随访90 d不良事件发生率低于对照组患者(χ 2/ P =4.294/0.045)。术后180 d,观察组、对照组患者左室射血分数均高于术前,且观察组较对照组明显升高( t =4.748,2.027,2.239, P =0.000,0.035, 0.039 );另外,术后180d观察组左室舒张末内径(LVEDD)、室间隔厚度(IVSd)明显低于对照组( t =1.985,2.223, P =0.049,0.039)。结论 冠状动脉内应用比伐卢定可进一步改善NSTEMI高危患者早期PCI术的预后,值得临床推广应用。
文摘Use of extracorporeal membrane oxygenation to support patients with critical cardiorespiratory illness is increasing.Systemic anticoagulation is an essential element in the care of extracorporeal membrane oxygenation patients.While unfractionated heparin is the most commonly used agent,unfractionated heparin is associated with several unique complications that can be catastrophic in critically ill patients,including heparin-induced thrombocytopenia and acquired antithrombin deficiency.These complications can result in thrombotic events and subtherapeutic anticoagulation.Direct thrombin inhibitors(DTIs)are emerging as alternative anticoagulants in patients supported by extracorporeal membrane oxygenation.Increasing evidence supports DTIs use as safe and effective in extracorporeal membrane oxygenation patients with and without heparininduced thrombocytopenia.This review outlines the pharmacology,dosing strategies and available protocols,monitoring parameters,and special use considerations for all available DTIs in extracorporeal membrane oxygenation patients.The advantages and disadvantages of DTIs in extracorporeal membrane oxygenation relative to unfractionated heparin will be described.
